latest news releases from the newsroom
Calypso Wireless, Inc.
New Technology Could Dramatically Boost Global Wireless Handset Sales -- Calypso Wireless Already in Negotiations with a Major OEM Manufacturer
MIAMI LAKES, Fla., March 3, 2004 (PRIMEZONE) -- Calypso Wireless, Inc. (Other OTC:CLYW), announced today that it is in the process of contacting all major OEMs in the wireless industry to notify them of the patent that could have a significant and immediate impact on the development of the industry, as well as major implications on the way OEM's such as Nokia (NYSE:NOK), Ericsson (Nasdaq:ERICY) and Motorola (NYSE:MOT) do business. Last week, Calypso Wireless announced it had been granted U.S. Patent #6,680,923 titled "Communication system and method", which covers the seamless roaming of voice, video and data between Wide Area Network access points, such as cellular towers (GSM/GPRS/EDGE, CDMA, WCMDA etc.) and short-range Internet access points (such as Wi-Fi, Bluetooth, etc.). Calypso Wireless is already in negotiations with a major OEM manufacturer to license its ASNAP(tm) technology. Due to the patent, even those OEM manufacturers that don't wish to license Calypso's technology at the time, but plan to create wireless devices that roam seamlessly between these networks, will have to obtain rights from Calypso Wireless.
NetCom Lowers Prices for Pre-Paid SMS
STOCKHOLM, Sweden, March 3, 2004 (PRIMEZONE) -- TeliaSonera's subsidiary NetCom is reducing the price on pre-paid SMS an additional 0.10 NOK to 0.69 NOK per SMS. This means that all NetCom SMS users will now pay 0.69 NOK per message.
Basilea Pharmaceutica Ltd
Positive Phase II Results for Basilea's Novel First-In-Class Antibiotic
BASEL, Switzerland, March 3, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG today announced positive phase II results for BAL5788 in the indication of complicated skin and skin structure infections (cSSSI). BAL5788 is the first of a new class of broad-spectrum cephalosporin antibiotics also active against multi-resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). In March 2003 the FDA awarded BAL5788 Fast Track review status in recognition of its therapeutic potential to treat severe infections.
Ahold Divests Thai Operation, Withdrawal from Asia Completed
ZAANDAM, The Netherlands, March 03, 2004 (PRIMEZONE) -- Ahold today announced it has reached agreement on the sale of its stake in CRC.Ahold, operating in Thailand, to its partner, the Central Group. The divestment, which is effective immediately, is the final step in the overall sale of Ahold's Asian operations. The transaction sum was not disclosed.